Printed From:

1. START TOUJEO®

Select a patient type to see initial dosing information.

Weight-based dosing for insulin-naive patients starting Toujeo®
T1DM
1/3 to 1/2 of the patient’s total daily dose (TDD) of insulin with Toujeo®
  • TDD = 0.2 to 0.4 Units/kg
  • Mealtime insulin should be used to satisfy the remainder of daily insulin requirements

T2DM
0.2 Units/kg
unit conversion to start for patients with T1DM and T2DM switching to Toujeo®
80% of the total daily NPH dose to start for patients with T1DM and T2DM
icon
Preview a copy of the Dosing Guide to download

Determine a starting dose for an insulin-naïve patient based on body weight1,a

T2DM Dosing Calculator

Enter a patient’s body weight—in pounds—to calculate the recommended starting dose of Toujeo®

T2DM, type 2 diabetes mellitus.

aUnits of Toujeo® are rounded down to the nearest whole unit and are calculated based on a recommended starting dose of 0.2 Units/kg. For dosing information in specific populations, please see the full Prescribing Information for Toujeo® . The appropriate starting dose in insulin-naive adults with type 1 diabetes mellitus (T1DM) is: kg x (0.2-0.4) = units.

The dosage of other antidiabetic drugs may need to be adjusted when starting Toujeo® to minimize the risk of hypoglycemia. View additional dosing information in the full Prescribing Information.

2. TITRATE TOUJEO®

Set goals2

Per ADA, set titration goals
based on individualized
patient needsb

Individualize treatment1

Titrate according to
patient’s individualized
FPG goal

Adjust dose1

Titrate Toujeo® no more frequently
than every 3 to 4 days to minimize
the risk of hypoglycemia

  • The maximum glucose-lowering effect of Toujeo® may take up to 5 days to fully manifest in T1DM1
    • In T1DM, the first Toujeo® dose may be insufficient to cover metabolic needs in the first 24 hours
  • After changing from Lantus® to Toujeo®, patients may experience a temporary rise in fasting plasma glucose (FPG) in the first weeks of therapy1
  • In clinical trials, patients started on or changed to Toujeo® required a higher dose of basal insulin than patients controlled with Lantus®
icon Pen
Order samples to help get your patients started with Toujeo®

If prior authorization is required by a patient’s insurance plan, help is available. Access Sanofi Patient Connection™

bAmerican Diabetes Association (ADA) glycemic recommendations for fasting or premeal plasma glucose for nonpregnant adults with diabetes: 80-130 mg/dL. More or less stringent goals may be appropriate for individual patients.